Amanote Research
Register
Sign In
Utilities for Health States in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma and Factors Influending Utility Values
Value in Health
- United Kingdom
doi 10.1016/j.jval.2015.03.1206
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
May 1, 2015
Authors
I. Choi
S. Park
J. Song
J.H. Jun
D. Suh
Publisher
Elsevier BV
Related search
Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Cost-Utility Analysis of IEV Drug Regimen Versus ESHAP Drug Regimen for the Patients With Relapsed and Refractory Hodgkin and Non-Hodgkin’s Lymphoma in Iran
Iranian Journal of Cancer Prevention
Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Nivolumab for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Pulmonary Toxicity in Paediatric Patients With Relapsed or Refractory Hodgkin Lymphoma Receiving Brentuximab Vedotin
British Journal of Haematology
Hematology
Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey
Annals of Hematology
Medicine
Hematology
Treatment of Relapsed and Refractory Hodgkin Lymphoma – Recommendations of the Czech Hodgkin Lymphoma Study Group
Klinicka Onkologie
Oncology
Cd19/Cd20-Redirected Bispecific Car T Cell Treatment in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Treating Hodgkin Lymphoma in the New Millennium: Relapsed and Refractory Disease
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
